Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Daratumumab and hyaluronidase-fihj + Dexamethasone + Lenalidomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Daratumumab and hyaluronidase-fihj | Darzalex Faspro | Daratumumab/rHuPH20|HuMax-CD38-rHuPH20|darzalex/rHuPH20 | CD38 Antibody 20 | Darzalex Faspro (Daratumumab and hyaluronidase-fihj) is a combination of the anti-CD38 antibody Daratumumab with hyaluronidase, which may be administered subcutaneously (PMID: 32213342). Darzalex Faspro (Daratumumab and hyaluronidase-fihj) is FDA approved as a monotherapy or in combination with lenalidomide and dexamethasone, or with pomalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with Kyprolis (carfilzomib) and dexamethasone, or with bortezomib, lenalidomide, and dexamethasone for patients with multiple myeloma, and in combination with bortezomib, cyclophosphamide and dexamethasone in patients with newly diagnosed light chain amyloidosis (FDA.gov). |
Dexamethasone | Adexone | Desametasone | ||
Lenalidomide | Revlimid | IMiD-1 | Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05561387 | Phase III | Daratumumab and hyaluronidase-fihj + Dexamethasone + Lenalidomide Bortezomib + Dexamethasone + Lenalidomide Daratumumab and hyaluronidase-fihj Lenalidomide | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Recruiting | USA | 0 |